F-group (family)
2003.1.1.38 THF_DHG_CYH_C
Ligands and drugs
955
Member domains
96
with ligand contacts (≤ 4 Å)
10.1% of members
66
with DrugDomain annotations
6.9% of members
53
with a DrugBank compound
5.5% of members
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
Chemical profiles are computed for X-groups. 2003.1.1.38 belongs to X-group 2003 Rossmann-like, which binds 8.9 ligand superclasses per 20 proteins, broader than 78% of the 256 X-groups with enough proteins to compare. View its chemical profile →
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB03461 | NAP | Nicotinamide adenine dinucleotide phosphate | 23 |
| DB14128 | NAD | Nadide | 11 |
| DB00116 | — | — | 2 |
| DB00157 | — | NADH | 2 |
| DB02338 | NDP | NADPH | 2 |
| DB04322 | 21V | LY249543 | 2 |
| DB04447 | DTT | 1,4-Dithiothreitol | 2 |
| DB00563 | MTX | Methotrexate | 1 |
| DB02358 | L37 | LY374571 | 1 |
| DB02363 | ATR | 2'-Monophosphoadenosine-5'-Diphosphate | 1 |
| DB02377 | GUN | Guanine | 1 |
| DB16833 | ADP | Adenosine disphosphate | 1 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| NAP | NADP NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE | 42 |
| NAD | NICOTINAMIDE-ADENINE-DINUCLEOTIDE | 21 |
| 9L9 | (2S)-2-[[4-[[2,4-bis(azanyl)-6-oxidanylidene-1H-pyrimidin-5-yl]carbamoylamino]phenyl]carbonylamino]pentanedioic acid | 12 |
| J49 | (2S)-2-[[4-[(4-azanyl-6-oxidanyl-pyrimidin-5-yl)carbamoylamino]phenyl]carbonylamino]pentanedioic acid | 8 |
| A1L22 | (2~{S})-2-[[4-[[2,4-bis(azanyl)-6-oxidanylidene-1~{H}-pyrimidin-5-yl]carbamoylamino]phenyl]carbonylamino]-4-(1~{H}-1,2,3,4-tetrazol-5-yl)butanoic acid | 6 |
| A1L23 | (2~{S})-2-[[4-[[2,4-bis(azanyl)-6-oxidanylidene-1~{H}-pyrimidin-5-yl]carbamoylamino]-3-chloranyl-phenyl]carbonylamino]pentanedioic acid | 6 |
| A1L24 | (2~{S})-2-[[4-[[2,4-bis(azanyl)-6-oxidanylidene-1~{H}-pyrimidin-5-yl]carbamoylamino]-3-chloranyl-phenyl]carbonylamino]-4-(1~{H}-1,2,3,4-tetrazol-5-yl)butanoic acid | 6 |
| A1L25 | (2~{S})-2-[[4-[[2,4-bis(azanyl)-6-oxidanylidene-1~{H}-pyrimidin-5-yl]carbamoylamino]-3-methyl-phenyl]carbonylamino]pentanedioic acid | 6 |
| CL | CHLORIDE ION | 6 |
| C3R | Carolacton | 4 |
| L34 | 4-(7-AMINO-9-HYDROXY-1-OXO-3,3A,4,5-TETRAHYDRO-2,5,6,8,9B-PENTAAZA-CYCLOPENTA[A]NAPHTHALEN-2-YL)-PHENYLCARBONYL-GLUTAMIC ACID | 4 |
| BQC | 5-(4-oxo-2-phenyl-1,5,7,8-tetrahydropyrido[4,3-d]pyrimidine-6(4H)-carbonyl)-1,3-dihydro-2H-2lambda~6~,1-benzothiazole-2,2-dione | 2 |
| BQF | 4-(5-oxo-1,5-dihydro-2H-[1]benzopyrano[3,4-c]pyridine-3(4H)-carbonyl)benzoic acid | 2 |
| D8C | N-[2-chloranyl-4-[[7-methyl-8-(4-methylpiperazin-1-yl)-5-oxidanylidene-2,4-dihydro-1H-chromeno[3,4-c]pyridin-3-yl]carbonyl]phenyl]methanesulfonamide | 2 |
| DTT | 2,3-DIHYDROXY-1,4-DITHIOBUTANE | 2 |
| IOD | IODIDE ION | 2 |
| J4C | (2S)-2-[[4-[[1-[(3,4-dichlorophenyl)methyl]-3,7-dimethyl-2,6-bis(oxidanylidene)purin-8-yl]amino]phenyl]carbonylamino]pentanedioic acid | 2 |
| J4F | 3-[4-[[1-[(4-chloranyl-1H-indol-2-yl)methyl]-3,7-dimethyl-2,6-bis(oxidanylidene)purin-8-yl]amino]-6-methyl-pyrimidin-2-yl]propanoic acid | 2 |
| J4L | 1-(3,4-dichlorobenzyl)-8-(((1R,4R)-4-hydroxycyclohexyl)amino)-3,7-dimethyl-3,7-dihydro-1H-purine-2,6-dione | 2 |
| KUK | (2~{S})-2-[[5-[[2,4-bis(azanyl)-6-oxidanylidene-5~{H}-pyrimidin-5-yl]carbamoylamino]pyridin-2-yl]carbonylamino]-4-(1~{H}-1,2,3,4-tetrazol-5-yl)butanoic acid | 2 |